A new study revealed that Fc-engineered anti-CTLA-4 mAb (with high ADCC activity) was able to increase the anti-tumor immunity in vitro in humans and in vivo in mice by decreasing CTLA-4hi effector Tregs, whereas anti-CTLA-4 mAbs with much less or no ADCC activity did not exhibit the increment (85). The gene discussed is CTLA4; the disease is neoplasm.